Randomized, double-blind, placebo-controlled, efficacy and safety study of etripamil self-administration for the termination of episodes of paroxysmal supraventricular tachycardia in chinese patients

Back

EHRA Premium Access

Randomized, double-blind, placebo-controlled, efficacy and safety study of etripamil self-administration for the termination of episodes of paroxysmal supraventricular tachycardia in chinese patients

Session: Supraventricular tachycardia

Topic: Treatment

Speaker: Doctor N. Li (Beijing, CN)

Event: EHRA 2025

Congress Presentation

Add to my library

About the speaker

Doctor Nan Li

Beijing Anzhen Hospital, Beijing (China)

0 follower

6 more presentations in this session

The impact of predictors used in differentiation between paroxysmal supraventricular tachycardia and ischemic heart disease in young patients with elevated high-sensitive troponin

Speaker: Doctor A. Ceviker (Istanbul, TR)

A large footprint catheter toggling between pulsed field and radiofrequency energy: first clinical experience for inappropriate sinus node tachycardia ablation

Speaker: Professor C. de Asmundis (Brussels, BE)

Long-term outcomes and efficacy of focal atrial tachycardia originating from the aortic root compared to right and left atrial FAT

Speaker: Mr M. Truhan (DE)

Zero X ray approach for the ablation of Supraventricular Tachycardia performed exclusively by wOmen OPerators: The STOOP Multicenter Registry

Speaker: Doctor S. Poggi (Napoli, IT)

Prevalence of stroke and mortality in patients with atrial tachycardia: insights from the SATELLITE Study Group

Speaker: Doctor A. Kahle (Duesseldorf, DE)

Access the full session

Supraventricular tachycardia

Speakers: Doctor N. Li, Doctor A. Ceviker, Professor C. de Asmundis, Mr M. Truhan, Doctor S. Poggi...

Access

About the event

EHRA 2025

30 March - 1 April 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources